CENPA-driven transcriptional activation of ECT2 enhances EGFR inhibitor resistance in lung adenocarcinoma
Biochemical and Biophysical Research Communications · 2025
DOI: 10.1016/j.bbrc.2025.152287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2025. Verfasst von Mingming Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Nanjing Gaochun People's Hospital, Nanjing, 211300, Jiangsu, China. Electronic address: mingtze@1…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Adenocarcinoma of Lung, Lung Neoplasms, Transcriptional Activation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
This research aims to uncover the molecular mechanisms by which centromere protein A (CENPA) and epithelial cell transforming 2 (ECT2) contribute to EGFR inhibitor resistance in lung adenocarcinoma (LUAD). Differentially expressed genes (DEGs) related to EGFR inhibitor resistance in LUAD were identified through analysis of the GSE153183 dataset. RT-qPCR and Western blot (WB) were performed to detect CENPA expression in osimertinib-resistant cells. A osimertinib-resistant cell line was developed by exposure to increasing concentrations of commercially obtained Osimertinib, and the drug sensitivity was evaluated using the CCK-8 assay. CENPA knockdown was achieved via lentiviral delivery, and its effects on cell proliferation, apoptosis, migration, and invasion were evaluated. The transcriptional regulation of ECT2 by CENPA was confirmed through dual-luciferase reporter assays and chromatin immunoprecipitation (ChIP). ECT2 was exogenously overexpressed in CENPA-silenced cells, and its effects on EGFR inhibitor resistance, epithelial-mesenchymal transition (EMT), and cancer stemness transformation were assessed. In vivo experiments were conducted to validate the findings. A marked upregulation of CENPA expression in osimertinib-resistant LUAD cells was detected. Silencing CENPA markedly enhanced EGFR-TKI Sensitivity, suppressed colony formation, increased apoptosis, and diminished migration and invasion. Mechanistically, CENPA promoted the expression of ECT2 via transcriptional regulation. Both in vitro and in vivo assays demonstrated that ECT2 overexpression counteracted the chemosensitizing effects of CENPA knockdown and mitigated epithelial-mesenchymal transition (EMT) and cancer stemness transformation in the osimertinib-resistant cells. CENPA promotes EGFR inhibitor resistance in LUAD by upregulating ECT2, which facilitates EMT and stemness transformation. Disruption of the CENPA-ECT2 pathway emerges as a new mechanism underlying EGFR inhibitor resistance, providing promising targets for therapeutic intervention in LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Nanjing Gaochun People's Hospital, Nanjing, 211300, Jiangsu, China. Electronic address: mingtze@126.com.
- Department of Pulmonary and Critical Care Medicine, Nanjing Gaochun People's Hospital, Nanjing, 211300, Jiangsu, China.
Zitieren
APA
Zhao, M., Hang, Y., Zheng, H., Yang, L., Yang, M., Chen, G., Wu, G., Kong, M., & Wang, N. (2025). CENPA-driven transcriptional activation of ECT2 enhances EGFR inhibitor resistance in lung adenocarcinoma. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2025.152287
Vancouver
Zhao M, Hang Y, Zheng H, Yang L, Yang M, Chen G, et al. CENPA-driven transcriptional activation of ECT2 enhances EGFR inhibitor resistance in lung adenocarcinoma. Biochemical and Biophysical Research Communications. 2025. doi:10.1016/j.bbrc.2025.152287
BibTeX
@article{Zhao2025,
author = {Zhao, Mingming and Hang, Yanping and Zheng, Haixia and Yang, Liangfeng and Yang, Minmin and Chen, Gang and Wu, Guozhu and Kong, Miaomiao and Wang, Nan},
title = {CENPA-driven transcriptional activation of ECT2 enhances EGFR inhibitor resistance in lung adenocarcinoma},
journal = {Biochemical and Biophysical Research Communications},
year = {2025},
doi = {10.1016/j.bbrc.2025.152287}
}
EUVIMED